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This study aimed to investigate the possible therapeutic effects and active components of Lycium barbarum
polysaccharides (LBP) on a high fat diet-induced NASH rat model. We induced NASH in a rat model by
voluntary oral feeding with a high-fat diet ad libitum for 8 weeks. After 8 weeks, 1 mg/kg LBP was orally
administered for another 4 weeks with a high-fat diet.When comparedwithNASH rats treated for 12weeks,
therapeutic LBP treatment for 4 weeks during 12 weeks of NASH induction showed ameliorative effects on:
(1) increased body and wet liver weights; (2) insulin resistance and glucose metabolic dysfunction; (3)
elevated level of serum aminotransferases; (4) fat accumulation in the liver and increased serum free fatty
acid (FFA) level; (5) hepatic fibrosis; (6) hepatic oxidative stress; (7) hepatic inflammatory response; and (8)
hepatic apoptosis. These improvements were partially through the modulation of transcription factor
NF-kB, MAPK pathways and the autophagic process. In a palmitate acid-induced rat hepatocyte steatosis
cell–based model, we also demonstrated that l-arabinose and b-carotene partially accounted for the
beneficial effects of LBP on the hepatocytes. In conclusion, LBP possesses a variety of hepato-protective
properties which make it a potent supplementary therapeutic agent against NASH in future clinical trials.
N
on-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the world, par-
ticularly in affluent areas. It is not only linked to othermetabolic disorders (e.g. type 2 diabetes), but it also
contributes to the late-stage liver diseases including cirrhosis and hepatocellular carcinoma (HCC)1.
When inflammatory and fibrotic responses are activated in the liver, NAFLD progresses to non-alcoholic
steatohepatitis (NASH) which may also induce severe cellular oxidative stress, necrosis and apoptosis2. To date,
the detailed pathological mechanisms for the development of NASH remain poorly understood. Recently, a
‘‘multiple-parallel-hit’’ theorywas proposed inwhich dysregulated lipidmetabolism and insulin resistance are the
first hit to the liver, followed by a ‘‘second-hit’’ or ‘‘multi-hits’’ such as oxidative stress, inflammation, apoptosis
and fibrosis3. Currently, there are two major therapeutic strategies for NAFLD/NASH: (1) lifestyle interventions
(including weight reduction, dietary modification and physical exercise) and (2) pharmaceutical therapy.
However, a successful management is based on appropriate combination of these therapies according to the
personal variation of specific patient4.
During the past decades, applying natural products to treat NASH received wide attention since some of them
exhibited effective outcomes with controlled side effects, including coffee5, garlic6,7, green tea8, milk thistle9 and
resveratrol10. Polysaccharide portion fromwolfberry (Lycium barbarum polysaccharides, LBP) is a newmedicinal
herbal derivative, which is reported to possess positive effects in nourishing the liver andmaintaining the health of
the eyes11. It also plays a protective role in hepatoma cancer cell line12 and the neuron system13. Recently, we have
reported that LBP protected rodent’s liver from carbon tetrachloride-induced acute liver injury14 and high-fat
diet-induced NASH15. Although we demonstrated that co-administration with LBP evidently attenuated hepatic
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steatosis, fibrosis, oxidative stress, inflammation, and apoptosis in
NASH rats, we still do not know (1) whether LBP could play a
therapeutic role against the development of NASH; and (2) what
are the effective specific monomers that account for the hepatic
beneficial effects of LBP15? In the current study, we mainly focused
on the therapeutic effects and mechanisms of LBP on an already
established NASH rat model. In addition, we also applied an in vitro
steatosis cell-based model in normal rat hepatocyte line BRL-3A and
investigated the possible protective effects of two LBP components,
such as l-arabinose and b-carotene.
Methods
Reagents and antibodies. All cell culture consumables and reagents were bought
from either Corning Incorporated (Corning, NY) or Gibco (Carlsbad, CA).
Antibodies against phosphorylated SMAD2 at Ser467, total SMAD2, total SMAD4,
and b-actin were bought from Santa Cruz Biotechnology (Santa Cruz, CA).
Phosphorylated SMAD4 at Thr277 antibody was purchased from Abnova (Taipei,
Taiwan). Resistin antibodywas ordered fromAbcam (Cambridge, UK). Antibodies of
nitrotyrosine, phosphorylated IRS-1 at Ser307, total IRS-1, phosphorylated GSK3a at
Ser21, total GSK3a, phosphorylated p38 MAPK at Thr180/Tyr182, total p38 MAPK,
phosphorylated JNK at Thr183/Tyr185, total JNK, phosphorylated ERK1/2 at
Thr202/Tyr204, total ERK1/2, IkBa, cleaved caspase-3, cytochrome c, p62, beclin-1,
Atg5, phosphorylated mTOR at Ser2448, and total mTOR were purchased from Cell
Signaling (Beverly, MA). Synaptophysin antibody was bought from DAKO
(Glostrup, Denmark).
Animal experiments. Healthy adult female Sprague-Dawley (SD) rats with a body
weight ranging from 180–200 g were obtained from the Laboratory Animal Unit
(LAU), The University of Hong Kong. Rats were maintained and cared for in
compliance with the requirements of The University of Hong Kong and the National
Institute of Health guidelines. The entire experimental procedures were conducted
according to the protocols approved by the Committee of Animal Use for Research
and Teaching at The University of Hong Kong. The Laboratory Animal Unit of The
University of Hong Kong is fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International (AAALAC International).
The animals were divided into six groups (n 5 6 per group) namely: (1) control
group (rats were fed with regular rat diet and tap water for 12 weeks); (2) vehicle-LBP
group (1 mg/kg LBP in 1 3 PBS; oral gavage feeding; one time per day during the
entire experimental duration); (3) vehicle-therapeutic LBP group (1 mg/kg LBP in 1
3 PBS; oral gavage feeding; one time per day from the 9th week to the 12th week); (4)
NASH group (rats were fed with a high-fat diet for 12 weeks); (5) NASH1 LBP group
(high-fat diet feeding with 1 mg/kg LBP in 13 PBS; oral gavage feeding; one time per
day during the entire experimental duration); and (6) NASH 1 therapeutic LBP
group (high-fat diet feeding with 1 mg/kg LBP in 1 3 PBS; oral gavage feeding; one
time per day from the 9th week to the 12th week). The entire experimental duration was
12 weeks. Open liver biopsy was performed on the 8th week under intraperitoneal
injection of anesthesia (Ketamine and Xylazine). The development of NASH in rats,
including the recipe and preparation protocols of diet, was performed based on our
previously described voluntary oral feeding NAFLD animal model15,16. The diet
consists of 9.3 g AIN-93MX (Dyets incorporation, Bethlehem, PA), 2.6 g AIN-93VX
(Dyets), 0.5 g choline bitatrate (Dyets), 1.1 g DL-methione (Bio-serv, Frenchtown,
NJ), 57.5 g lactalbulmine hydrolysate (Bio-serv), 117.5 g dextrose (Dyets), 36.6 ml
fish oil (Sigma), and 4.5 g suspending agent K (Bio-serv) in per 1,000 ml volume.
Regular chow for rat (PicoLabH Rodent Diet 20) was purchased from LabDiet
(LabDiet, Brentwood, MO). The calories of regular chow were provided by 25% from
protein, 13% from fat, and 62% from carbohydrates, while the calories of high-fat diet
were provided by 35% from protein, 30% from fat, and 35% from carbohydrates. The
selection of LBP dose was based on our previous studies on both acute and chronic
liver models14,15. After twelve weeks, rats were killed by an overdose of anesthesia
(150 mg/kg pentobarbital, intraperitoneal injection) according to the protocols
approved by the Committee of Animal Use for Research and Teaching at The
University of Hong Kong after a 12-hr fasting. Blood and liver samples were collected
for further analyses.
Processing of blood and tissue samples. Serumwas collected by centrifugation from
whole blood sample at 1,0003 g for 10 min at 4uC and stored at 280uC. Liver tissue
samples were fixed in 10% phosphate-buffered formalin, processed for histology and
embedded in paraffin blocks. Five-micrometer tissue sections were cut and stained
with hematoxylin and eosin (H&E), Sirius red and synaptophysin (DAKO,Denmark)
for histological analysis using a LEICA Qwin Image Analyser (Leica Microsystems
Ltd., Milton Keynes, UK). The NAFLD activity score (NAS) of each group was
calculated as previously described17.
Serum ALT and AST assay. To evaluate the hepatic injury at the enzymatic level,
serum ALT and AST levels were measured by using ALT (SGPT) and AST (SGOT)
reagent sets (Teco diagnostics, Anaheim, CA) according to manufacturer’s
instructions.
Free fatty acids (FFA) assay. To study the effect of LBP on lipid metabolism, serum
FFA level of each rat was measured by using a Cayman free fatty acids assay kit
(Cayman chemical, Ann Arbor, MI) and the final results were expressed as mM in the
serum.
Measurement of MDA level. Levels of the end-product of lipid peroxidation
(malondialdehyde, MDA) in all liver tissue samples were determined by using a
Bioxytech LPO-586TM kit (Oxis Research, Portland, OR). The reaction product was
measured spectrophotometrically at 586 nm. Standard curves were constructed using
1,1,3,3-tetraethoxypropane as a standard. The MDA levels were normalized with
corresponding protein amounts determined by a Bio-Rad Protein Assay Kit (Bio-
Rad, Hercules, CA) and expressed as percentage against the control level.
Insulin tolerance test (ITT) and glucose tolerance test (GTT). Measurements of
ITT and GTT were performed as previously described18 with modifications in
accordance to the Vanderbilt recommendations for evaluating glucose homeostasis19.
Briefly, after 12-week NAFLD induction, rats were placed in clean cages under
starvation state but with water supply for 6 hrs. Then rats subjected to ITT or GTT
assays were intraperitoneally (i.p.) injected with recombinant insulin (a fixed bolus of
0.17 IU, R&D systems, Minneapolis, MN) or D-glucose (a fixed bolus of 350 mg,
Sigma-Aldrich, St. Louis, MO), respectively. We used a fixed bolus of insulin or
glucose because lean body mass (e.g. muscle, liver, and brain) was the main site of
glucose disposal, even though obesity was primarily caused by an increase in fat mass.
Administering glucose on a per body weight basis would increase the glucose dose
disproportionately in relation to the major glucose-utilizing tissue19. 0, 20, 40, 60, 80
and 100 min after insulin/glucose injection, tail vein blood sample from each rat was
tested for glucose level directly by using ACCU-CHEK blood glucose monitoring
system (Roche Diagnostic, Basel, Switzerland). Serum insulin levels were quantified
by using the commercial ELISA kits from Antibody and Immunoassay Services of
The University of Hong Kong (Hong Kong, China). Basal plasma glucose
concentrations were also recorded to normalize the results of GTT19.
ELISA assay. ELISA measurements of TNF-a, IL-1b, and MCP1 were performed by
using corresponding ELISA development kits from PeproTech (PeproTech Inc.,
Rocky Hill, NJ) according to user instructions. COX-2 ELISA assay was conducted
with kit from EIAab (Wuhan EIAab Science, Wuhan, China). TGF-b1 and a-SMA
ELISA kits were from eBioscience (San Diego, CA) and MyBioSource (San Diego,
CA), respectively.
Western blot. Western blot analyses of liver tissue extracts were performed as
described6. The ratio of the optical density of the protein product to the internal
control (b-actin) was obtained and was expressed as ratio or percentage of the control
value in the Figures.
NF-kB activity. The activity of transcription factor NF-kB p65 was measured with a
NF-kB/p65 ActivELISA kit from IMGENEX Corporation (San Diego, CA) according
to user’s instructions.
Cell culture and treatments. The rat hepatocyte BRL-3A cell line was supplied by the
Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai,
China) and cultured in RPMI-1640 with 10% (v/v) FBS at 37uC and 5% CO2 using a
cell incubator. When cells reached a confluence of 60–70%, they were divided into 8
groups (n 5 5) including: (1) control group (with PBS which was the dissolvent for
LBP); (2) steatosis group [treated with palmitate acid (PA)]; (3) vehicle-LBP group
(treated with LBP only); (4) steatosis 1 LBP group (treated with PA and LBP); (5)
vehicle-arabinose group (treated with 3 mM l-arabinose only); (6) steatosis 1
arabinose group (treated with PA and 3 mM l-arabinose); (7) vehicle-carotene group
(treated with 2 mM b-carotene only); and (8) steatosis1 carotene group (treated with
PA and 2 mM b-carotene). The treatment duration was 24 hrs. The lipid
accumulation in each group was revealed by Oil Red O staining. The dose selection of
l-arabinose20 and b-carotene21 was based on previous in vitro reports.
MTT assay.Cell viability was evaluated by the conversion of 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) to a purple color
product by cellular mitochondria. After drug treatment, cells from each group were
washed by sterile PBS 3 times and then incubated with 5 mg/ml MTT for 3 hrs, and
subsequently dissolved in dimethyl sulfoxide (DMSO). The absorbance of MTT was
measured at 570 nm.
Glucose production assay. After treatment, cells were washed by sterile PBS for 3
times to remove glucose, and then incubated for 16 hrs in glucose production
medium (glucose- and phenol red-free DMEM containing gluconeogenic substrates,
20 mM sodium lactate, and 2 mM sodium pyruvate) in the presence of 1 nM insulin
(R&D systems) during the last 4 hrs. The concentration of glucose was measured
using a commercial kit from Sigma. Glucose concentration was normalized with
corresponding cellular protein concentration.
Quantification of apoptotic cells. After drug treatment, Hoechst 33342 (5 mg/ml)
and propidium iodide (5 mg/ml) were added to each well to stain live cells. The results
were expressed as the percentage of apoptosis (PA): PA5 apoptotic cell number/total
cell number 3 100%22.
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Activities of caspase- 3/7.Activities of caspases-3 and -7 from both liver tissue lysates
and cell lysates were measured using Caspase-Glo 3/7 Assay Systems (Promega,
Madison, WI) according to the user’s manual. The luminescence was read in a
Glomax luminometer (Promega) and expressed as fold of change in caspase 3/7
activity from the control.
RNA extraction and quantitative PCR. Total RNA of each rat was extracted from
the liver sample or cell lysate by an using illustraTM RNAspin mini kit (GE healthcare,
UK). The preparation of the first-strand cDNA was conducted following the
instruction of the SuperScriptTM First-Strand Synthesis System (Invitrogen, Calsbad,
CA). The mRNA expression levels of target genes were measured by a Takara SYBR
premix Taq quantitative PCR system (Takara Bio Inc, Shiga, Japan) using a MyiQ2
real-time PCR machine (Bio-Rad). The primer sequences and annealing
temperatures used in these real-time PCR reactions are listed in Suppl. Table S1.
Parallel amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as the internal control. Relative quantification was done by using the 22DDCt
method. The relative expression of the specific gene to the internal control was
obtained and then expressed as a percentage of the control value in the Figures. All
real-time PCR procedures including the design of primers, validation of PCR
environment and quantification methods were performed according the MIQE
guideline23.
Statistical analysis. Data from each group were expressed as means 6 SEMs. The
trapezoidal rule was used to determine the area under the curve (AUC). Statistical
comparisons between groups were done using the Kruskal–Wallis test followed by
Dunn’s post hoc test to detect differences in all groups. A p, 0.05 was considered to
be statistically significant (Prism 5.0, Graphpad software, Inc., San Diego, CA, USA).
Results
Confirmation of NASH induced by an 8-week high-fat diet feed-
ing. To make sure the successful establishment of NASH lesions in
the rat liver, liver biopsy of high-fat diet fed rats was performed at the
end the 8th week, before the start of the ‘‘therapeutic’’ administration
of LBP. It is shown that high-fat diet induced evident hepatic
histopathological changes in the liver, such as lipid accumulation,
foci of inflammatory cells and necrosis (Supplementary Figures 1A
and 1B). TheNAS score of the liver from the high-fat diet fed rats was
significantly higher than those of the normal rats fed with a regular
animal chow fed (Supplementary Figure 1C).
LBP treatments ameliorated rat obesity and insulin resistance.
Eight-week consumption of high-fat diet induced significant in-
crease in body weight of the rats when compared with the control
rats fed with a regular rat diet (365.0 6 9.8 g versus 326.36 11.6 g at
8 weeks, p , 0.05). Administration of 1 mg/kg LBP significantly
reduced the body weight of NASH rats from the 3rd week to the
12th week (340.2 6 13.4 g [LBP-treated] versus 401.7 6 10.7 g
[NASH-treated] at the 12th week, p , 0.05). For the therapeutic
treatment of LBP, which started from the 9th to 12th week, also
significantly reduced the body weight of high-fat diet fed rats
(352.1 6 14.0 g [LBP-treated] versus 401.7 6 10.7 g [NASH-
treated] at the 12th week, p , 0.05) (Figure 1A). Administration of
LBP in both LBP-treated groups (NASH-LBP 12 weeks and NASH-
LBP 9-12week) did not influence the body weight when compared
with the control rats (data not shown). Results of wet liver weight
further confirmed the anti-obesity effect of LBP. The wet liver weight
of NASH rats was significantly higher than that of the control rats
(13.46 0.1 g versus 11.56 0.3 g, p, 0.05). Both LBP-treated groups
reduced the liver weight of NASH rats comparable to control level
(Figure 1B). Interestingly, for most weeks, administration of LBP did
not influence the appetite of NASH rats. There was no significant
difference in the daily food intake volume between LBP-treated
NASH rats and NASH rats without LBP except for weeks 3, 4 and
11 (Figure 1C).
In NASH rats, injection of recombinant insulin caused impaired
insulin metabolism/clearance when compared with the control and
vehicle-LBP rats (Supplementary Figure 2B). Treatments with LBP
significantly improved the insulin clearance impairment induced by
NASH (Supplementary Figure 2B). In addition, from the results of
blood glucose and its AUC areas, LBP treatments effectively
improved insulin resistance (Figure 1E and 1F). Similarly, after
normalization with basal glucose level, we found that dysregulated
glucose metabolism in NASH rats was also evidently corrected by
LBP administration in both treated groups (Figure 1G and 1H,
Supplementary Figure 2A). To further investigate the pathways
involved in the improvement of insulin and glucose metabolism,
we measured the change of resistin and IRS-1/GSK3a pathways in
all groups. It was found that high-fat diet significantly increased the
protein level of resistin and the phosphorylation level of GSK3a. It
also decreased the phosphorylation of IRS-1. LBP administration,
either co-treatment or delayed-treatment, counter-acted the effects
of high-fat diet on these pathways without influencing the total pro-
tein level of IRS-1 and GSK3a (Figure 1D).
LBP treatments improved hepatic injury. Hepatic H&E staining
results showed that 12-week administration of high-fat diet caused
typical NASH pathological phenotypes of the rat’s liver, including a
large number of lipid droplet accumulation, infiltration of inflamma-
tory cells and necrosis of hepatocytes (Figure 2A). All of the time
points in LBP treatment (from week 1 to week 12) significantly im-
proved the hepatic histopathology after 12 weeks, and exhibited
cellular architecture comparable to the control. Interestingly, thera-
peutic LBP treatment from week 9 to week 12 also dramatically
ameliorated the severity of lipid deposition and reduced inflamma-
tory foci and cellular necrosis in the liver. There was no statistical
difference between the NAS score of two groups of LBP treatments
(NASH-LBP 12 weeks and NASH-LBP 9-12week; Figure 2C). Sirius
red staining found that the collagen formation in the liver of NASH
rats was significantly more than those of the control rats. Both
treatment groups of LBP effectively reduced the collagen forma-
tion, leading to attenuation of hepatic fibrosis (Figures 2B and 2D).
Consistently, NASH rats exhibited the highest level of serum ALT
level, which was significantly reduced by both groups of LBP
treatment (Figure 2E). For the AST level, there was no significant
variation among all groups of rats (Figure 2F).
LBP treatments alleviated hepatic fibrosis. To further investigate
the molecular mechanisms underlying the reduction of hepatic
fibrosis by LBP, the expressional change of the TGF-SMAD path-
way was firstly assessed. The protein expression of both TGF-b1 and
a-SMAwas up-regulated by the induction of NASH (Figures 3A and
3B).Western blot assay also showed that the phosphorylation level of
both SMAD2 and SMAD4 was increased in the NASH group
(Figure 3C). Treatments with LBP, either with NASH-LBP 12
weeks or therapeutically (NASH-LBP 9–12 weeks), significantly
reduced the phosphorylated level of these proteins without influ-
encing their basal levels. In addition, since the formation of hepatic
fibrosis is closely associated with the activation of hepatic stellate cells
(HSCs), we then quantified the number of activated HSCs in each
group by staining synaptophysin, a novel marker for activated HSCs
in the liver24. The number of synaptophysin-positive in the NASH
groupwas significantly higher than other five groups, predominantly
around the centrolobular vein areas (Figure 3D). Both groups of LBP
treatment (NASH-LBP 12 weeks and NASH-LBP 9-12 weeks)
reduced the number of activated HSCs comparable to the control
level (Figure 3E). LBP showed no obvious effect on the fibrotic
change of healthy rats except a small reduction of the a-SMA
protein level (Figure 3B).
Hepatic lipid accumulation and oxidative stress were attenuated
by LBP. To explore the underlying mechanisms for the attenuated
hepatic lipid accumulation by both groups of LBP treatment (NASH-
LBP 12 weeks and NASH-LBP 9–12 weeks), expressional changes of
lipogenic genes (SREBP-1c and PPARc2) and lipolytic genes (ATGL
and adiponectin) were measured. Induction of NASH significantly
increased the hepatic mRNA expression of SREBP-1c and PPARc2,
while reduced the mRNA expression of ATGL and adiponectin,
leading to a net increase of the serum FFA level (Figures 4A–4E).
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Figure 1 | LBP therapeutically improved NASH-induced obesity, insulin resistance and glucose metabolism dysfunction. (a) The body weight of each
rat was recorded every week throughout the 12-week high-fat diet induction of NASH. (b) After the induction, the wet liver weight was weighed for
each rat. (c) The food intake of each rat (inml/d)was recorded everyday throughout the 12-week high-fat diet induction ofNASH. Each dot represents the
average food intake of a week. (d) Representative Western blot results of resistin, phosphorylated IRS-1, total IRS-1, phosphorylated GSK3a, and total
GSK3a in all group of rats from 3 repeated Western blot experiments. (e) Blood glucose level was assessed after an intraperitoneal (i.p.) injection
with recombinant insulin (a fixed bolus of 0.17 IU) and the serum glucose level was recorded 0, 20, 40, 60, 80, and 100 min later after the 12-week
induction of NASH. (f) Area under the curve for glucose (AUCglucose) was calculated using the trapezoidal rule. (g) Blood glucose level of each rat was
recorded 0, 20, 40, 60, 80, and 100 min after an i.p. injection of D-glucose (a fixed bolus of 350 mg) after the 12-week induction of NASH. Data were
normalized with basal glucose levels. (h) AUCglucose was calculated using the trapezoidal rule. Data from each group were expressed as means 6 SEMs (n
5 6). Statistical comparisons between groups were done using the Kruskal–Wallis test followed by Dunn’s post hoc test to detect differences in all groups. A
p, 0.05 was considered to be statistically significant. ‘‘*’’ represents significant change against control and ‘‘#’’ represents significant change against either
LBP co-treatment group or LBP after-treatment group. Different letters (e.g. a and b) mean a statistical significant change between each other.
www.nature.com/scientificreports
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Figure 2 | LBP therapeutically ameliorated hepatic injury and fibrosis. (a) Typical H&E staining results of each group of rat. Yellow arrows indicate
hepatic fat accumulation and red arrow indicates typical inflammatory infiltration in the liver sections. Magnification: 3200. Bar: 20 mm. (b) Typical
Sirius red staining results of each group of rat. Magnification: 3200. Bar: 20 mm. (c) NAFLD activity scores (NAS) of each group of rat after NASH
induction and LBP treatments. (d) Collagen staining quantification of each group of rat after NASH induction and LBP treatments, as shown by the Sirius
red staining. (e,f) Serum ALT and AST levels in each group. Data from each group were expressed as means 6 SEMs (n 5 6). Statistical comparisons
between groups were done using the Kruskal–Wallis test followed byDunn’s post hoc test to detect differences in all groups. Different letters (e.g. a and b)
mean a statistical significant change (p , 0.05) between each other. TLBP: therapeutic LBP treatment from the 9th week to the 12th week with NASH
induction.
www.nature.com/scientificreports
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In line with the attenuated steatosis in the liver, the influence of
NASH on lipid metabolic genes was abolished in both groups of
LBP treatment (Figures 4A–4D). Thus, the serum level of FFA was
regulated to the healthy rat level (Figure 4E). LBP treatments did not
affect the rats without NASH development (Figures 4A–4E).
Lipid peroxidation and induced oxidative stress are common con-
sequences of steatosis and insulin resistance during the progression
of NASH25. To test the possible antioxidant property of LBP, the
mRNA levels of endogenous antioxidant enzymes CAT and GPx
were assessed firstly. InNASH rats, the hepatic level of these enzymes
was significantly down-regulated, exhibiting an impaired defense
against hepatic oxidative stress (Figures 4F and 4G). Administra-
tion of LBP, either along with or after the establishment of the
NASH induction, effectively restored the levels of both antioxidant
enzymes. Thenwemeasured the products of lipid peroxidation (hep-
atic MDA content) and nitric oxide pathway (hepatic nitrotyrosine
formation) in all groups of rats. NASH rats showed elevated content
of both MDA and nitrotyrosine, indicating an increased status of
hepatic lipid peroxidation and oxidative stress. Both groups of LBP
treatment significantly reduced or even abolished such elevation of
oxidative stress markers (Figures 4H and 4I).
Treatments with LBP attenuated hepatic inflammation and apop-
tosis through NF-kB. The main pathological discrepancy between
steatosis and NASH is the occurrence of hepatic inflammation. To
address the anti-inflammatory effect of LBP, we selected three pro-
inflammatory markers (TNF-a, IL-1b and COX-2) and one
chemokine marker (MCP-1) in all groups of rats for ELISA assays.
As expected, the expressions of these proteins were significantly
elevated by NASH induction, which were either abolished or
significantly attenuated by the co-treatment or delayed-treatment
with LBP (Figures 5A–5D). Consistently, hepatic level of cleaved
caspase-3, the direct marker for apoptosis, was increased in the
NASH rats, indicating the occurrence of hepatic apoptosis.
Administrations of LBP effectively reduced its level (Figure 5G).
To further explore the mechanism, we tested the expressional
change of the intrinsic apoptotic pathway. We found that pro-
gression of NASH increased the protein level of cytochrome c and
the mRNA level of pro-apoptotic molecule Bax, while decreased in
the mRNA level of anti-apoptotic molecule Bcl-2. Both groups of
LBP treatment showed significantly reversal of such effects
(Figures 5G–5I). Since transcription factor NF-kB is the master
regulator of both inflammatory and apoptotic responses, we then
measured the activity of its subunit p65 in the nuclear protein. The
activity of p65 in NASH group was significantly higher than that of
the control group (Figure 5F), indicating an activated status of NF-
kB. It was accompanied by a low level of IkBa, the cytosolic inhibitor
of NF-kB (Figure 5E). Addition of LBP markedly reduced NF-kB
activity and restored the level of IkBa.
LBP treatments enhanced autophagy and regulated the MAPK
pathways. Since autophagy is beneficial for delaying the progres-
sion of NASH7, we measured several key autophagic markers in all
rats. It is shown thatNASH induction in the rat liver up-regulated the
expression of autophagic markers including Atg5 and LC3 II, with
down-regulation of autophagic negative regulators including
phosphorylated mTOR and p62. The influence of NASH on
beclin-1 expression was not obvious (Figure 5J). In both groups of
LBP treatment (NASH-LBP 12 weeks and NASH-LBP 9-12 weeks),
the cellular autophagy was further potentiated, when compared to
their expressions in the NASH group (Figure 5J). Vehicle-LBP
treatments did not obviously affect the autophagic markers in the
healthy rats.
To further investigate the therapeutic property of LBP, we mea-
sured three key members (p38 MAPK, JNK and ERK1/2) of the
MAPK family. In the NASH group, the phosphorylation levels of
both p38 MAPK and JNK were increased, but then decreased to the
control level by the administration of LBP (Figure 5K). The phos-
phorylation of ERK1/2, in contrast, was down-regulated by NASH
induction. Both groups of LBP treatment showed further reduction
Figure 3 | Molecular pathways accounted for the anti-fibrotic effects of LBP. (a,b) Expressional changes of hepatic TGF-b1 and a-SMA in each group of
rat using ELISA kits. (c) Typical Western blot results of the expressional changes of SMAD2/4 in each group of rat from 3 repeated Western blot
experiments. Full-length blots are presented in Supplementary Fig. 4. (d) Representative synaptophysin staining result in each group. Synaptophysin is a
marker for activated hepatic stellate cells. Arrows indicate typical positive staining. Magnification: 3200. Bar: 20 mm. (e) Quantitative results for the
synaptophysin staining. Data from each group were expressed as means 6 SEMs (n 5 6). Statistical comparisons between groups were done using the
Kruskal–Wallis test followed by Dunn’s post hoc test to detect differences in all groups. Different letters (e.g. a and b) mean a statistical significant change
(p , 0.05) between each other. TLBP: therapeutic LBP treatment from the 9th week to the 12th week with NASH induction.
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in its phosphorylation level without affecting its total level
(Figure 5K).
L-arabinose and b-carotene partially accounted for the hepatic
therapeutic effects of LBP. To demonstrate the active mono-
mer(s) that account(s) for the hepatic therapeutic properties of
LBP against NASH development, we applied an in vitro cellular
steatosis model using sodium palmitate (SP) as the inducer in rat
hepatocyte cell line BRL-3A26. After 24-hr incubation, it was found
that SP caused evident fat accumulation, with reduced cell viability in
a dose-dependent manner (Supplementary Figure 3). Considering
the balance between obvious fat accumulation and acceptable cell
viability, we chose 0.35 mM SP as the optimum dose in the follow-
ing in vitro studies. As shown in Figure 6B, application of SP
significantly reduced the cell viability from ,100% to ,72%. Co-
treatment with LBP restored the cell viability comparable to the
control level (,95%). Although not as potent as LBP, treatment
with l-arabinose or b-carotene also significantly recovered the cell
status to ,84% or,85%, respectively. In addition, incubation with
SP also caused fat accumulation in the cultured BRL-3A cells, which
was significantly attenuated by co-treatment with LBP, either with l-
arabinose or b-carotene (Figures 6A and 6C). These treatments alone
did not influence the normal cells (Figures 6A–6C).
To further characterize the beneficial roles of l-arabinose and b-
carotene, we assessed the insulin and glucose metabolism pathways
of the cell. Exposure of BRL-3A cells to SP enhanced gluconeogen-
esis, which was reduced by LBP or b-carotene treatment (Figure 6D).
Western blot results of resistin and phosphorylated IRS-1 further
confirmed that SP incubation significantly induced the up-regulation
of resistin and the impairment of IRS-1 signaling. Addition of LBP, l-
arabinose or b-carotene partially counter-acted these effects. Total
protein level of IRS-1 was not influence by these treatments
(Figure 6E). In addition, SP incubation caused the increased level
of GSK3a phosphorylation, which was partially reduced by the co-
treatment of LBP or b-carotene, without affecting its total protein
level (Figure 6E). These data indicated that SP incubation induced
impaired insulin and glucose metabolism in BRL-3A cells. LBP, l-
arabinose and b-carotene, partly ameliorated such impairments.
Similar to the results from the animal model, incubation with SP
significantly reduced the expression of CAT and increased the level
of TNF-a and cellular apoptosis. Changes of cellular caspase-3/7
activity further proved these findings (Figures 7A–7D). LBP, l-
arabinose or b-carotene treatment either abolished or significantly
counteracted the effects of SP, although in most cases, LBP showed
better alleviative effects than the other two monomers (Figures 7A–
7D).
Discussion
Since the initiation and progression of NAFLD/NASH is a slow and
progressive process, using an appropriate therapy that can target
most of its key pathological events (e.g. insulin resistance, lipid
deposition, fibrosis and inflammation) and combined with specific
Figure 4 | LBP therapeutically re-balanced lipid metabolism and attenuated hepatic oxidative stress. (a,b) Expressional changes of lipogenic markers
SREBP-1c and PPARc2 in the liver of each rat, measured by quantitative PCR. (c,d) Expressional changes of lipolytic markers ATGL and adiponectin in
the liver of each rat,measured by quantitative PCR. (e) Serum free fatty acid (FFA) levelmeasured by a commercial kit in all rats after 12-week experiment.
(f,g) The mRNA expressional changes of hepatic antioxidant enzymes catalase (CAT) and glutathione peroxidase (GPx) from each rat. (h) Hepatic
malondialdehyde (MDA) level in each rat after 12-week experiment. (i) RepresentativeWestern blot results of nitrotyrosine formation in the liver of each
rat from 3 repeatedWestern blot experiments. Full-length blots are presented in Supplementary Fig. 4. Data from each group were expressed as means 6
SEMs (n5 5). Statistical comparisons between groups were done using the Kruskal–Wallis test followed byDunn’s post hoc test to detect differences in all
groups. Different letters (e.g. a and b)mean a statistical significant change (p, 0.05) between each other. C: control, N:NASH, L: vehicle-LBP, NL:NASH
1 LBP treatment throughout the experiment, TL: vehicle-LBP treatment from the 9th week to the 12th week with NASH induction, NTL: NASH 1 LBP
treatment from the 9th week to the 12th week with NASH induction.
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exercise plan, should theoretically reverse or retard the process of
fatty liver to a nearly healthy condition4,27. Here we showed that LBP
could therapeutically attenuate a spectrum of NASH phenotypes,
from up-stream insulin resistance to down-stream hepatic apoptosis
in both in vivo and in vitro systems.
Insulin resistance and glucose metabolism impairment are found
in most NAFLD/NASH patients. It is characterized by a reduce
insulin sensitivity in the whole body, liver and adipose tissues. In
the liver, it mainly causes excess dietary fat, enhanced delivery of free
fatty acids to the liver, diminished fatty acid oxidation, and increased
de novo lipogenesis28,29. In this study, from GTT (with both normal-
ized glucose and insulin levels) and ITT readouts, both groups of LBP
administration (NASH-LBP 3 12 weeks and post-NASH/LBP 3 4
weeks) potently improved insulin sensitivity and glucosemetabolism
in the NASH rats (Figure 1 and Supplementary Figure 2). Thera-
peutic LBP treatment exhibited comparable ameliorative effects as
with the LBP co-treated rats. In NASH rats, apart from the above
changes, this was accompanied by the impaired hepatic signaling of
IRS-1 and activated signaling of GSK3a, key molecules in insulin
resistance and glucose metabolism, respectively30,31. Furthermore,
the excessive hepatic fat accumulation and serum FFA enhancement
were significantly attenuated by LBP treatments. Molecular markers
for fatty acid biosynthesis and utilization also revealed the re-
balancing of the lipid metabolism by LBP (Figs. 2 and 4). These
results were consistent with our previous findings15 and other reports
showing the beneficial effects of LBP on steatosis32,33.
Figure 5 | LBP therapeutically ameliorated hepatic inflammatory responses and apoptosis through modulating autophagy and MAPK pathway.
(a–d) Protein expressional changes of inflammatory and chemoattractive responses markers tumor necrosis factor-alpha (TNF-a), interleukin-1 beta
(IL-1b), cyclooxygenase-2 (COX-2) andmonocyte chemotactic protein-1 (MCP-1) from each group of rats after 12-week experiment. (e) Representative
Western blot results of inhibitor of NF-kB alpha (IkBa) formation in the liver of each group of rats from 3 repeatedWestern blot experiments. Full-length
blots are presented in Supplementary Fig. 4. (f) Changes of nuclear factor-kappa B (NF-kB) subunit p65 in each group of rats, as measured by EIA kit.
(g) Representative Western blot results of cleaved caspase-3 and cytochrome c (cyto c) in rats with different treatments from 3 repeated Western blot
experiments. Full-length blots are presented in Supplementary Fig. 4. (h,i) Changes of mRNA expression level of intrinsic apoptotic markers Bcl-2 and
Bax in each group of rats. (j) Representative Western blot results of key autophagic markers including phosphorylated mTOR, total mTOR, beclin 1,
Atg5, LC3II, and p62 in each group of rats from 3 repeated Western blot experiments. Full-length blots are presented in Supplementary Fig. 4.
(k) RepresentativeWestern blot results of keyMAPKmarkers including phosphorylated and total forms of p38MAPK, JNK and ERK1/2 in each group of
rats from 3 repeatedWestern blot experiments. Full-length blots are presented in Supplementary Fig. 4. Beta-actin was used as the internal control. Data
from each groupwere expressed asmeans6 SEMs (n5 5 or 6). Statistical comparisons between groups were done using the Kruskal–Wallis test followed
by Dunn’s post hoc test to detect differences in all groups. Different letters (e.g. a and b) mean a statistical significant change (p , 0.05) between each
other. C: control, N: NASH, L: vehicle-LBP, NL: NASH 1 LBP treatment throughout the experiment, TL: vehicle-LBP treatment from the 9th week to the
12th week with NASH induction, NTL: NASH 1 LBP treatment from the 9th week to the 12th week with NASH induction.
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Figure 6 | LBP, l-arabinose and b-carotene prevented cellular steatosis and insulin/glucose metabolism dysfunction in a palmitate acid-induced cell
model. (a) Representative image of sodium palmitate-induced fat accumulation in rat hepatocyte cell line BRL-3A after 24-hr incubation. Fat droplets
were stained byOil RedO.Magnification: 3100. Bar: 10 mm. (b) Cellular viability measured byMTT conversion in BRL-3A cells with different treatment
for 24 hrs. (c) Quantitative Oil Red O (normalized by MTT results) in BRL-3A cells with different treatment for 24 hrs. In addition, (d) Glucose
production and (e) change of the resistin, IRS-1/GSK3a pathways were measured in BRL-3A cells with different treatment for 24 hrs. Data from each
groupwere expressed asmeans6 SEMs (n5 5). Statistical comparisons between groups were done using the Kruskal–Wallis test followed byDunn’s post
hoc test to detect differences in all groups. Different letters (e.g. a and b) mean a statistical significant change (p , 0.05) between each other.
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Fibrosis is one of the major features of fatty liver diseases.
Activation of HSCs and following PI3K/Akt/FoxO1 pathway con-
tributes to the initiation of fibrosis, with well-characterized TGF-b/
SMAD pathway34,35. We found that high-fat diet significantly
enhanced the collagen formation in the liver (Figure 2), which was
accompanied by elevated levels of the TGF-b/SMAD pathway and
HSCs activation (Figure 3). When LBP was administered along with
or after the establishment of NASH, it evidently ameliorated the
formation of hepatic collagen through inhibition of these signaling
pathways. Thus, LBP may share similar mechanistic pathways with
other hepato-protective herbal derivatives, such as green tea on fib-
rotic attenuation8.
It is well-known that NF-kB is a major sensor and regulator of
oxidative stress, inflammation and apoptosis36,37. The activation of
NF-kB relies on the degradation of its cytosolic inhibitor IkBa. In the
current study, high-fat diet induced NASH rats showed enhanced
activity of p65 and promoted the degradation of IkBa, indicating an
activated status of NF-kB, accompanied with the occurrence of oxid-
ative stress, inflammation and apoptosis in the liver (Figures 4 and 5).
Similar with our previous studies using garlic, green tea extract, and
LBP itself6,8,15, supplementation of LBP, either protectively or thera-
peutically, significantly alleviated hepatic oxidative stress, inflam-
matory response and apoptosis during NASH development
partially through NF-kB inhibition. Since dysregulated lipid meta-
bolism may induce lipid peroxidation, directly leading to oxidative
stress, inflammation and apoptosis, the beneficial function of LBP on
lipid metabolism may also partly explain the attenuated hepatic
injury by LBP treatment38.
In recent years, the beneficial property of autophagy in NAFLD/
NASH development drew much attention because it counteracted
the effect of apoptosis, and also hepato-protective drug treatment
usually enhances the activity of autophagy, as we demonstrated in the
garlic study7. A recent paper using ULK1 knockoutmice also pointed
out that impairment of the autophagic signaling significantly influ-
enced the therapeutic effects of resveratrol on NAFLD mice39. In
accordance to these studies, our two approaches of LBP treatment
also enhanced the autophagic pathway activity (including beclin 1,
Atg 5 and LC3II) through the degradation ofmTOR,when compared
with the NASH rat group. Furthermore, the expression level of
autophagic substrate p62 was down-regulated by NASH develop-
ment and further decreased by treatments with LBP, indicating the
enhanced autophagy in the liver from another aspect40.
Similar to most Traditional Chinese Medicine recipes, LBP is a
mixture of severalmonomers including glucose, arabinose, galactose,
mannose, xylose, rhamnose and/or fucose41,42. It also contains other
antioxidants such as zeaxanthin dipalmitate, b-cryptoxanthin palmi-
tate, zeaxanthinmonopalmitate, and b-carotene43,44. Previous studies
have extensively examined the beneficial properties of LBP on tumor,
neuronal system and the liver. However, none of them characterized
the effective components of LBP. In the current study, we firstly
found that l-arabinose and b-carotene partially represented the
active functional components of LBP in lipid, insulin and glucose
metabolism, oxidative stress, inflammation and apoptosis in a pal-
mitate acid-induced cellular steatosis model (Figures 6 and 7).
Although LBP showed stronger protection than l-arabinose or b-
carotene, our current results demonstrated the active beneficial func-
Figure 7 | LBP, l-arabinose and b-carotene attenuated cellular oxidative stress, inflammation and apoptosis induced by sodium palmitate.
(a) Catalase (CAT) mRNA, (b) Tumor necrosis factor-alpha (TNF-a), (c) Apoptotic ratio (apoptotic cell number against total cell number)
and (d) Cellular caspase-3/7 activity were measured in BRL-3A cells with different treatment for 24 hrs. Data from each group were expressed as
means 6 SEMs (n 5 5). Statistical comparisons between groups were done using the Kruskal–Wallis test followed by Dunn’s post hoc test to detect
differences in all groups. Different letters (e.g. a and b) mean a statistical significant change (p , 0.05) between each other.
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tions of its components for the possible treatment of liver diseases
such as NAFLD and NASH.
Together, our findings showed a potent therapeutic and hepato-
protective effect of LBP in ameliorating a spectrum ofNASH induced
hepatic abnormalities, including (1) increased body and liver
weights; (2) hepatic insulin resistance and glucose metabolism dys-
function; (3) elevated level of serum aminotransferases; (4) fat accu-
mulation in the liver and increased serum FFA level; (5) hepatic
fibrosis; (6) hepatic oxidative stress; (7) hepatic inflammatory res-
ponse; and (8) hepatic apoptosis. These improvements were partially
through the modulation of transcription factor NF-kB, MAPK path-
ways and the autophagic processes. Importantly, LBP not only alle-
viated hepatic injury when administered along with the induction of
NASH, but also therapeutically recovered liver functions on an estab-
lished NASH condition. In vitro studies exhibited the beneficial
properties of LBP partly ascribed to the functions of l-arabinose
and b-carotene. Thus, daily consumption of LBP should be consid-
ered as a promising way to prevent and retard the initiation and
progression of NASH.
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